SEC Form 4 · accession 0001144204-17-048089
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David D O'Toole
Officer — Chief Financial Officer
Period of report
Sep 12, 2017
Accepted (ET)
Sep 14, 2017 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $36.00 | Sep 12, 2017 | A | 150,000 | A | Sep 12, 2018 | Sep 11, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1On September 12, 2017, the reporting person was granted an option to purchase 150,000 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant.